Drug Profile
MX 33501
Alternative Names: MX 3350 1Latest Information Update: 23 Aug 2006
Price :
$50
*
At a glance
- Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Developer MaxoCore Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 22 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)
- 14 Oct 2003 No development reported - Preclinical for Cancer in USA (unspecified route)